Is it better to invest in mid-cap or small-cap?

It all depends on your risk tolerance. Mid-cap stocks are generally less volatile than small-cap stocks, but the possibility for big gains is often greater with smaller companies.

Is there a mid-cap ETF?

Yes, the Vanguard Mid-Cap ETF and the iShares S&P Mid-Cap 400 Growth ETF are two low-cost mid-cap funds.

Should I invest in mid-cap stocks?

A diversified portfolio may include mid-cap stocks, depending on your goals and risk tolerance. In general, mid-caps can be a nice way to balance stable large-cap stocks with more volatile small-caps.

Do mid-cap stocks do well in a recession?

During a recession, mid-caps generally do better than small-caps, but not as well as large-caps. Of course, their performance depends heavily on their sector; a mid-cap consumer staples stock, for example, is likely to outperform a large-cap industrials stock.

What is the average return on a mid-cap stock?

According to Morningstar, mid-caps have recorded an 11% annualized return since the 1991 launch of the Russell Midcap index -- better than small caps (9.05%) or large caps (10.4%).

Who should invest in mid caps?

Mid-cap stocks are an ideal tool for diversifying a portfolio that's heavily weighted to small- and large-cap stocks. They're also a nice balance for investors with a moderate risk tolerance level.

Which sectors typically have strong mid-cap stocks?

The technology, healthcare, and consumer discretionary stocks are among the strongest performers in the mid-cap space.

3 Top Mid-Cap Stocks for 2026 and How to Invest

By Frank Bass – Updated Jun 17, 2026 at 11:05 AM EST | Fact-checked by Margo Winton Parodi

Key Points

Mid-cap stocks balance growth potential and stability, ideal for diversifying portfolios.
Invest in mid-cap ETFs for broad exposure to growing yet stable mid-market companies.
Consider mid-caps for possible high returns and manageable volatility in long-term investing.

Loading paragraph...

Table by author.

Loading table...

Loading paragraph...

Ticker Information Table
Name and ticker	Market cap	Dividend yield	Industry
Ambarella (NASDAQ:AMBA)	$3.4 billion	0.00%	Semiconductors and Semiconductor Equipment
CRISPR Therapeutics (NASDAQ:CRSP)	$5.8 billion	0.00%	Biotechnology
Iridium Communications (NASDAQ:IRDM)	$5.7 billion	1.12%	Diversified Telecommunication Services

Data as of Jul 3, 2026. Showing 3 of 3 total entries.

Loading ticker_table...

1. Ambarella

Loading paragraph...

NASDAQ: AMBA

Ambarella

Today's Change

(-11.30%) $-9.98

Current Price

$78.36

Key Data Points

Market Cap

$3.4B

Day's Range

$76.86 - $91.29

52wk Range

$48.30 - $96.69

Volume

2.3M

Avg Vol

1.4M

Gross Margin

57.79%

Loading company_card...

Ambarella (AMBA -11.41%) is a relatively small company in a market segment -- semiconductors, or computer chips -- that is dominated by giants. Ambarella isn't a chipmaker itself; rather, it designs components that then get manufactured by its chip fabrication partners.

Specifically, Ambarella focuses on computer vision (CV) semiconductors, which use artificial intelligence (AI) to help a computer system "see," or recognize what's in a field of vision, and make decisions based on that information. Applications include security cameras and autonomous vehicles, with the latter expected to be a huge growth market in the next couple of decades.

In the "past performance is no guarantee of future results" category, Ambarella stock almost doubled from early April to late May 2026, peaking near $97. But the company's shares had given up about 30% of their gains by mid-June as investors became concerned about its high cash burn rate and R&D spending.

2. CRISPR Therapeutics

Loading paragraph...

NASDAQ: CRSP

CRISPR Therapeutics

Today's Change

(7.77%) $4.32

Current Price

$59.94

Key Data Points

Market Cap

$5.8B

Day's Range

$56.24 - $61.68

52wk Range

$44.12 - $78.48

Volume

106.4K

Avg Vol

1.7M

Gross Margin

-528340.24%

Loading company_card...

CRISPR Therapeutics (CRSP +8.02%) is a biotechnology company co-founded by a Nobel Prize–winning chemist who helped develop the gene-editing technology known as clustered regularly interspaced short palindromic repeats, or CRISPR.

Biotech stocks are notoriously volatile, but CRISPR Therapeutics is considered among the best in class, largely due to its winning the first Food and Drug Administration approval for its Casgevy gene-editing therapy for sickle cell anemia. It's partnered with Vertex Pharmaceuticals (VRTX +6.13%), which expects growth that should easily top Casgevy's 2025 total revenue of $116 million. So while CRISPR posted disappointing revenue figures in the fourth quarter of 2025, its shares have held more or less steady, based on investor confidence in its future prospects.

Despite its successes, investors should tread carefully. CRISPR is still unprofitable, posting -$1.28 earnings per share for the first quarter of 2026, slightly below analyst expectations. It's likely to remain a bumpy ride, as clinical updates, regulatory news, and changes in investor sentiment continue to affect share prices. With a market cap of about $5.3 billion in mid-June 2026, investors are paying a premium for future growth.

3. Iridium Communications

Loading paragraph...

NASDAQ: IRDM

Iridium Communications

Today's Change

(-3.54%) $-1.97

Current Price

$53.75

Key Data Points

Market Cap

$5.7B

Day's Range

$53.38 - $57.18

52wk Range

$15.64 - $57.18

Volume

3.3M

Avg Vol

2.8M

Gross Margin

47.33%

Dividend Yield

1.12%

Loading company_card...

Loading paragraph...

NYSEMKT: VO

Vanguard Mid-Cap ETF

Today's Change

(0.14%) $0.11

Current Price

$80.51

Key Data Points

Day's Range

$79.86 - $81.27

52wk Range

$69.36 - $81.55

Volume

3.6M

Loading company_card...

The Vanguard Mid-Cap ETF (VO +0.14%) tracks the performance of the CRSP US Mid Cap index. This fund holds both growth- and value-oriented companies and contained almost 300 stocks in mid-2026. It pays a small dividend and is affordable, with an expense ratio -- the fund's annual management fee -- of just 0.03%.

2. iShares S&P Mid-Cap 400 Growth ETF

Loading paragraph...

NYSEMKT: IJK

iShares Trust - iShares S&P Mid-Cap 400 Growth ETF

Today's Change

(-0.81%) $-0.94

Current Price

$115.13

Key Data Points

Day's Range

$114.03 - $117.59

52wk Range

$90.36 - $117.60

Volume

490.6K

Loading company_card...

Loading paragraph...

FAQ: Investing in Mid-Cap Stocks

Loading faq...

About the Author

Frank Bass is a contributing Motley Fool stock market analyst and editor covering energy, healthcare, consumer, and financial sectors. Frank has decades of experience in financial journalism, holding reporting and editing roles at The Wall Street Journal, The Associated Press, and Bloomberg. He also currently edits research on the global energy transition. He holds a bachelor’s degree in journalism from Texas Tech University and is a graduate student at the University of Alaska Fairbanks. Fun Facts: Frank has hiked The Long Trail in Vermont from end to end, and currently lives in a semi-dry cabin in Interior Alaska.

TMFEditFool

Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. The Motley Fool has positions in and recommends Meta Platforms and Vanguard Index Funds - Vanguard Mid-Cap ETF. The Motley Fool has a disclosure policy.

3 Top Mid-Cap Stocks for 2026 and How to Invest